J&J acquires California medical device company for $400Mnews2023-11-30T20:10:13+00:00November 30th, 2023|Endpoints News|
More companies need to set diversity enrollment goals in cancer trials, FDA saysnews2023-11-30T19:51:10+00:00November 30th, 2023|Endpoints News|
Drug prices in TV ads again? Senators take another swing with expedited billnews2023-11-30T19:40:42+00:00November 30th, 2023|Endpoints News|
Novo Nordisk ramps up legal case against compounding pharmacies selling ‘misbranded’ semaglutidenews2023-11-30T19:27:29+00:00November 30th, 2023|Endpoints News|
FDA ships Form 483 to generic drug giant Dr. Reddy’s due to equipment issues, other observationsnews2023-11-30T18:40:20+00:00November 30th, 2023|Endpoints News|
GSK is winning 70% of the RSV market, while Pfizer’s launch has left it ‘disappointed’ so farnews2023-11-30T18:13:08+00:00November 30th, 2023|Endpoints News|
2024 VC forecast: Clinical-stage CDMOs likely to have uptick in demand but specialization criticalnews2023-11-30T17:00:01+00:00November 30th, 2023|Endpoints News|
Charles River works on rare disease gene therapy; Emergent gets $75M for anthrax vaccine; EuroAPI hires new COO news2023-11-30T16:35:18+00:00November 30th, 2023|Endpoints News|
Flagship aims to raise $3B; Phenomic inks another pharma deal; Oncovita gets €8M for cancer vaccinenews2023-11-30T16:03:10+00:00November 30th, 2023|Endpoints News|
Cybin gears up for registrational trial of psilocybin analog in major depression after PhII successnews2023-11-30T16:02:34+00:00November 30th, 2023|Endpoints News|
